Mineralys TherapeuticsMLYS 35 Return-on-Tangible-Equity is -24.49% as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Mineralys Therapeutics ranks better than 57.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Mineralys Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-157.36 Mil. Mineralys Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $642.42 Mil. Therefore, Mineralys Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -24.49%.
The historical rank and industry rank for Mineralys Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
MLYS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -82.24 Med: -76.13 Max: -30.16
Current: -30.16
During the past 6 years, Mineralys Therapeutics's highest Return-on-Tangible-Equity was -30.16%. The lowest was -82.24%. And the median was -76.13%.
MLYS's Return-on-Tangible-Equity is ranked better than 57.05% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs MLYS: -30.16
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Mineralys Therapeutics Return-on-Tangible-Equity Related Terms
Mineralys Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Mineralys Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLYS vs VCEL, NRIX, PHVS: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Mineralys Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mineralys Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Mineralys Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -24.49% mean?
Mineralys Therapeutics (MLYS) has a Return-on-Tangible-Equity of -24.49% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #515 out of 1199 companies in the Biotechnology industry, placing it in the top 43%.
Is Mineralys Therapeutics' Return-on-Tangible-Equity too high?
Mineralys Therapeutics' current Return-on-Tangible-Equity is -24.49%. Based on the distribution chart, Mineralys Therapeutics ranks #515 out of 1199 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mineralys Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Return-on-Tangible-Equity compare to VCEL and NRIX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #515 out of 1199 companies for Return-on-Tangible-Equity. This puts Mineralys Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Return-on-Tangible-Equity is -24.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Return-on-Tangible-Equity of -24.49%. The current Return-on-Tangible-Equity is -24.49%. Mineralys Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Return-on-Tangible-Equity is -24.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
35GF Score
Get the complete analysis for MLYS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLYS has been successfully added to your 
